W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal Article
Increased p16 Levels Correlate with pRb Alterations in Human Urothelial Cells
Thomas R. Yeager,Walter M. Stadler,Cassandra D. Belair,Jairaj A. Puthenveettil,Olufunmilayo I. Olopade,Catherine A. Reznikoff +5 more
TL;DR: The hypothesis that p16 mediated cell cycle inhibition, as well as p16 regulation, occurs via pRb dependent pathway(s) is supported.
Vorinostat in Advanced Prostate Cancer Patients Progressing on Prior Chemotherapy (National Cancer
Deborah A. Bradley,Dana E. Rathkopf,Rodney L. Dunn,Walter M. Stadler,Glenn Liu,David Smith,Roberto Pili,James A. Zwiebel,Howard I. Scher,Maha Hussain +9 more
TL;DR: In this article, a phase 2 trial was designed to evaluate the efficacy of vorinostat in chemotherapy-pretreated patients with metastatic castration-resistant prostate cancer.
Journal Article
Transcriptional Profiles in Peripheral Blood Mononuclear Cells Prognostic of Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma
Michael E. Burczynski,Natalie C. Twine,Gary Dukart,Bonnie Marshall,Manuel Hidalgo,Walter M. Stadler,Theodore F. Logan,Janice P. Dutcher,Gary R. Hudes,William L. Trepicchio,Andrew Strahs,Fred Immermann,Donna K. Slonim,Andrew J. Dorner +13 more
TL;DR: In this paper, the authors evaluated the association of expression profiles in peripheral blood mononuclear cells (PBMCs) with clinical outcomes in patients with advanced renal cell cancer and found that the expression levels of many PBMC transcripts were predictors for the patient outcomes of time to progression and overall survival (time to death).
Journal ArticleDOI
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
Noura Choudhury,Alexa Campanile,Tatjana Antic,Kai Lee Yap,Carrie Fitzpatrick,James L. Wade,Theodore Karrison,Walter M. Stadler,Yusuke Nakamura,Peter H. O'Donnell +9 more
TL;DR: Afatinib demonstrated significant activity in patients with platinum-refractory UC with HER2 or ERBB3 alterations and deserves further investigation in molecularly selected UC.
Journal ArticleDOI
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Nieves Martinez Chanza,Wanling Xie,Mehmet Asim Bilen,Hannah Dzimitrowicz,Jarred Burkart,Daniel M. Geynisman,Archana Balakrishnan,I. Alex Bowman,Rohit Jain,Walter M. Stadler,Yousef Zakharia,Vivek Narayan,Benoit Beuselinck,Rana R. McKay,Abhishek Tripathi,Russell K. Pachynski,Andrew W. Hahn,Jo Ann Hsu,Sumit A. Shah,Elaine T. Lam,Tracy L. Rose,Anthony Mega,Nicholas J. Vogelzang,Michael R. Harrison,Amir Mortazavi,Elizabeth R. Plimack,Ulka N. Vaishampayan,Hans J. Hammers,Saby George,Naomi B. Haas,Neeraj Agarwal,Sumanta K. Pal,Sandy Srinivas,Benedito A. Carneiro,Daniel Y.C. Heng,Dominick Bossé,Toni K. Choueiri,Lauren C. Harshman +37 more
TL;DR: This real-world study provides evidence supporting the antitumour activity and safety of cabozantinib across non-clear-cell renal cell carcinoma subtypes and specific molecular alterations.